Literature DB >> 28058595

Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing.

Xiaopeng Yan1, Cong Shao1, Chuang Chen2,3, Jun Chen4, Shen Gu1, Luoshun Huang1, Xu Fu1, Hui Zhao2, Yudong Qiu5.   

Abstract

BACKGROUND: Gene data on infiltrative hepatocellular carcinoma (iHCC) are still unknown. AIMS: This study aims to identify the gene expression signature of iHCC compared with single nodular (SN)-type HCC according to the gross classification.
METHODS: The whole-exome sequencing was performed in six matched HCC tumor/normal pairs (three infiltrative type and three single nodular type) from six patients who received curative hepatectomy. Subsequent validation using Sanger sequencing and real-time PCR was performed in 30 HCC tumor samples (15 infiltrative type and 15 single nodular type).
RESULTS: Following whole-exome sequencing, Sanger sequencing, and bioinformatics analysis, it revealed significant difference of iHCC from SN-type HCC in gene patterns. Particularly, a typical growth factor receptor tyrosine kinase FGFR3 was predominantly mutated in iHCC. One nonsynonymous variant c.G285T (p.Q95H) and five additional mutations (c.G938A:p.G313D, c.G1291A:p.A431T, c.C1355G:p.T452R, c.C1377T:p.L459L, and c.A1445T:p.E482V) were investigated by whole-exome and Sanger sequencing, respectively. Immunohistochemical studies confirmed the specific expression of FGFR3 in iHCC samples.
CONCLUSION: Our studies indicated that FGFR3 may be a candidate oncogene in tumor progression and a promising therapeutic target in iHCC patients who had early recurrence.

Entities:  

Keywords:  Biomarker; FGFR3; Infiltrative hepatocellular carcinoma; Mutation signatures; Whole-exome sequencing

Mesh:

Substances:

Year:  2017        PMID: 28058595     DOI: 10.1007/s10620-016-4408-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation.

Authors:  K Shirabe; S Aishima; A Taketomi; Y Soejima; H Uchiyama; H Kayashima; M Ninomiya; Y Mano; Y Maehara
Journal:  Br J Surg       Date:  2011-02       Impact factor: 6.939

3.  Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.

Authors:  Benjamin Schmidt; Lan Wei; Danielle K DePeralta; Yujin Hoshida; Poh Seng Tan; Xiaochen Sun; Janelle P Sventek; Michael Lanuti; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Int J Cancer       Date:  2015-11-09       Impact factor: 7.396

4.  Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?

Authors:  Stevan A Gonzalez
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

5.  Response to transcatheter oily chemoembolization in hepatocellular carcinoma 3 cm or less: a study in 50 patients who underwent surgery.

Authors:  H Nakamura; T Liu; S Hori; H Mitani; T Murakami; T Kozuka; C Kuroda; M Monden; M Sakurai; K Wakasa
Journal:  Hepatogastroenterology       Date:  1993-02

6.  Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

Authors:  Christine Gauglhofer; Sandra Sagmeister; Waltraud Schrottmaier; Carina Fischer; Chantal Rodgarkia-Dara; Thomas Mohr; Stefan Stättner; Christoph Bichler; Daniela Kandioler; Fritz Wrba; Rolf Schulte-Hermann; Klaus Holzmann; Michael Grusch; Brigitte Marian; Walter Berger; Bettina Grasl-Kraupp
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 7.  Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma.

Authors:  Xiaopeng Yan; Yudong Qiu
Journal:  Cancer Lett       Date:  2015-08-14       Impact factor: 8.679

8.  Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

Authors:  Jakob Paur; Lisa Nika; Christiane Maier; Alexander Moscu-Gregor; Julia Kostka; Daniela Huber; Thomas Mohr; Petra Heffeter; Waltraud C Schrottmaier; Sonja Kappel; Daniela Kandioler; Klaus Holzmann; Brigitte Marian; Walter Berger; Michael Grusch; Bettina Grasl-Kraupp
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

9.  FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation.

Authors:  Xinyu Liu; Xiaoqian Jing; Xi Cheng; Ding Ma; Zhijian Jin; Weiping Yang; Weihua Qiu
Journal:  Med Oncol       Date:  2016-04-04       Impact factor: 3.064

10.  Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.

Authors:  A Parish; M Schwaederle; G Daniels; D Piccioni; P Fanta; R Schwab; K Shimabukuro; B A Parker; T Helsten; R Kurzrock
Journal:  Cell Cycle       Date:  2015-05-07       Impact factor: 4.534

View more
  3 in total

1.  CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Authors:  Hongliang Liu; Junwen Hu; Hua Pan; Dilai Luo; Mingwen Huang; Wei Xu
Journal:  Dig Dis Sci       Date:  2017-11-30       Impact factor: 3.199

2.  Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.

Authors:  Jakob Paur; Maximilian Valler; Rebecca Sienel; Karin Taxauer; Klaus Holzmann; Brigitte Marian; Andreas Unterberger; Thomas Mohr; Walter Berger; Andja Gvozdenovich; Johannes Schimming; Michael Grusch; Bettina Grasl-Kraupp
Journal:  Liver Int       Date:  2020-06-17       Impact factor: 5.828

3.  CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression.

Authors:  Hangwei Fu; Yida Zhang; Yin Chen; Junying Chen; Ping Chen
Journal:  Mol Med Rep       Date:  2020-11-17       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.